Provectus Biopharmaceuticals Inc (PVCT)

[Paulness]

NEWS -- Provectus Biopharmaceuticals Retains Allison+Partners as New Media Relations Consultant

Date : 06/02/2015 @ 6:00AM
Source : Business Wire
Stock : Provectus Biopharmaceuticals, Inc. (PVCT)

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that it has retained Allison+Partners as its new media relations consultant.

Peter Culpepper, CFO and COO of Provectus, said, “We are very happy to have retained Allison+Partners to take over our media relations efforts. As our pivotal phase 3 clinical trial of PV-10 as a treatment for melanoma gets underway, we believe that we have to devote greater resources to our contact with the public by way of the media. With PhRMA, the Pharmaceutical Research and Manufacturers of America, on its roster of clients, we are confident that Allison+Partners understands our communications needs and has the contacts and resources to raise our profile even higher.

Matthew Della Croce, President, Europe and Global Corporate for Allison+Partners, said, “Allison+Partners is very happy to add Provectus Biopharmaceuticals to its client list. It’s an exciting time in the development of PV-10, and we are happy to help the company and its management.”

About Allison+Partners

Allison+Partners, an MDC Partners company, is a global communications firm driven by a collaborative approach to innovation and creativity. The firm was named PRWeek’s 2015 “Midsize Agency of the Year,” In2 SABRE’s 2015 “Most Innovative Agency” and The Holmes Report’s 2014 “Agency of the Year.” Allison+Partners is organized around seven practices: Consumer Marketing, Corporate, Global China Practice, Health + Wellness, Public Affairs, Social Impact and Technology, and has offices in San Francisco, New York, London, Beijing, Shanghai, Paris, Lyon, Singapore, Chicago, Washington D.C., Silicon Valley, Seattle, Dallas, Los Angeles, Atlanta, Phoenix, Portland and San Diego. The agency also has a network and deep affiliations with firms worldwide through MDC Partners (NASDAQ: MDCA, Toronto Stock Exchange: MDZ.A), a progressive marketing and communications network, championing the most innovative entrepreneurial talent. For more information, visit http://www.allisonpr.com .

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, http://www.clinicaltrials.gov . For additional information about Provectus, please visit the Company’s website at http://www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:

• our determination, based on guidance from the FDA, whether to proceed with or without a partner with the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial if it is necessary to complete (versus interim data alone);
• our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver;
• our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with mechanism of action studies; and
• our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602005462/en/

Porter, LeVay & Rose, Inc.
Investor Relations
Marlon Nurse, 212-564-4700
DM, SVP
or
Media Relations
Todd Aydelotte, 646-428-0644
or
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
CFO, COO